European Commission approves Takeda's FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer.
European Commission approves Takeda's FRUZAQLA (fruquintinib) for treatment of previously treated metastatic colorectal cancer. The drug is indicated for patients who have been previously treated with standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. Takeda received approval from the CHMP on April 25, 2024, and the U.S. FDA in 2022.
June 21, 2024
5 Articles